Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

32P - Observational study to compare in vitro sensitivity to therapy in patients-derived organoids (PDOs) with real life outcome: The ChemoSenPDO study


16 Sep 2021


ePoster Display


Cytotoxic Therapy;  Targeted Therapy;  Translational Research

Tumour Site

Gastrointestinal Cancers;  Genitourinary Cancers;  Gynaecological Malignancies




Annals of Oncology (2021) 32 (suppl_5): S361-S375. 10.1016/annonc/annonc684


J. GARCIAS-DONAS1, Z. Dantes2, B. Jiménez3, M. Yagüe1, A. Manjunath2, L. Ferreira2, B. Hefel2, J. Slawska2, J.F. Rodríguez-Moreno4, E. Sevillano3, A. Barquin3, M. Dorta Suarez3, J. Rodriguez Pascual3, C. Millan5, I. Lopez5, L. Jimenez6, A. Müller5, M. Barba1, S. Ruiz-Llorente1, P. NAVARRO7

Author affiliations

  • 1 Genitourynary, Gynecologycal An Skin Tumors Unit, FUNDACION INVESTIGACION HM HOSPITALES, 28050 - MADRID/ES
  • 2 Laboratory, Invitrocue Europe AG, 81669 - Mubich/DE
  • 4 Medical Oncology Department, HM Hospitales-Centro Integral Oncológico Clara Campal, Madrid/ES
  • 5 Gynecology, HM Hospitales, 28050 - Madrid/ES
  • 6 Surgery, HM Hospitales, 28050 - Madrid/ES
  • 7 Genitourninary, Gynecologycal And Skin Tumors Unit, HM CIOCC - Centro Integral Oncológico Clara Campal, 08023 - Barcelona/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 32P


Despite recent advances in precision oncology, the majority of cases do not present druggable alterations. In such a scenario, treatments must be selected empirically with the only support of general guidelines. Functional tests, able to interrogate the in vitro sensitivity to different drugs of a tumor could help to rationalize this decision.


Onco-PDO© checks the sensitivity of a minimum eight drugs, and their combinations, selected by the attending physician among 100 different options in organoids derived from one given patient. The assay requires a fresh sample with a volume of 1cm3 obtained by surgery or percutaneous punction. After initial digestion, cells are grown as organoids and exposed to the drugs to establish the percentage of cell death induced by each individual drug. In this study, we aimed to compare the in-vitro results with the real outcome of patients.


From August 2019 to April 2021, 67 patients were recruited in four Spanish hospitals obtaining adequate samples in 52. The median age was 57 years (range 4 – 85), 18 were males and 34 females. Tumors included were ovarian cancer (49%), non-small cell lung cancer (24%) prostate cancer (7%), and others 20% (colorectal, melanoma, pancreas, granulosa cells, head-neck, and three pediatric tumors). Organoids could be established in 30 (58%) of the submitted cases. Focusing on the two main tumor types included the success rate for obtaining an OncoPDO© result was 42% in ovarian cancer and 77% in the lung. Drugs in monotherapy that achieved a 50% of cell death in vitro corresponded with clinical benefit in 32% of the cases. This number rose to 50% when assessing combinations.


Studying the in vitro drug sensitivity with patient-derived organoids could support a more rational selection of treatments. The observational design of our study, where patients could have received several lines of therapy before the sample for the study was obtained represent a major limitation that should be addressed in the future.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Fundacion Investigación HM Hospitales.


Invitrocue Europe AG.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.